Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation, which typically diminish over time with continued use
Doses of GLP-1 and Gcg that when administered alone did not affect food intake were given as a co-injection which resulted in a significant reduction in feeding and c-fos induction in both the area postrema and CeA
While just over 30% of people on Wegovy made it on their medication to the one-year mark in 2021, the year it was approved for weight loss, that figure had nearly doubled by 2024
We support every major GLP-1
Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations
On a GLP-1 it sits right in the middle of it, tugging on several of the same levers the medication is pulling